Role of protein kinase C in diabetic complications

References

• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes47(6), 859–866 (1998).
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Minchenko AG, Vasupuram R et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes52(3), 864–871 (2003).
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Wendt T, Harja E, Bucciarelli L et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of Type 2 diabetes. Atherosclerosis185(1), 70–77 (2006).
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science258(5082), 607–614 (1992).
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J.9(7), 484–496 (1995).
   PubMed Web of Science ®Google Scholar
• Keenan HA, Costacou T, Sun JK et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care30(8), 1995–1997 (2007).
   PubMed Web of Science ®Google Scholar
• Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem. J.332(Pt 2), 281–292 (1998).
   PubMed Web of Science ®Google Scholar
• Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA288(20), 2579–2588 (2002).
   PubMed Web of Science ®Google Scholar
• Sajan MP, Standaert ML, Rivas J et al. Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor κB (NFκB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance. Diabetologia52(6), 1197–1207 (2009).
   PubMed Web of Science ®Google Scholar
• Liscovitch M, Cantley LC. Lipid second messengers. Cell77(3), 329–334 (1994).
   PubMed Web of Science ®Google Scholar
• Nakanishi H, Brewer KA, Exton JH. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem.268(1), 13–16 (1993).
   PubMed Web of Science ®Google Scholar
• Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol.265(5 Pt 1), E783–E793 (1993).
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl Acad. Sci. USA89(22), 11059–11063 (1992).
   PubMed Web of Science ®Google Scholar
• Derubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes43(1), 1–8 (1994).
   PubMed Web of Science ®Google Scholar
• Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science272(5262), 728–731 (1996).
   PubMed Web of Science ®Google Scholar
• Craven PA, Davidson CM, DeRubertis FR. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes39(6), 667–674 (1990).
   PubMed Web of Science ®Google Scholar
• Ido Y, McHowat J, Chang KC et al. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes43(12), 1469–1477 (1994).
   PubMedGoogle Scholar
• Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes43(9), 1122–1129 (1994).
   PubMed Web of Science ®Google Scholar
• Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am. J. Physiol.261(4 Pt 2), F571–F577 (1991).
   Google Scholar
• Studer RK, Craven PA, DeRubertis FR. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes42(1), 118–126 (1993).
   PubMed Web of Science ®Google Scholar
• Konishi H, Tanaka M, Takemura Y et al. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc. Natl Acad. Sci. USA94(21), 11233–11237 (1997).
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature404(6779), 787–790 (2000).
   PubMed Web of Science ®Google Scholar
• Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol.212(2), 167–178 (2006).
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Xia P, Kunisaki M, Higashi S, Feener EP, King GL. Insulin’s effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am. J. Physiol.267(3 Pt 1), E369–E379 (1994).
   Google Scholar
• Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J. Clin. Invest.83(5), 1667–1675 (1989).
   PubMed Web of Science ®Google Scholar
• Whiteside CI, Dlugosz JA. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am. J. Physiol. Renal Physiol.282(6), F975–980 (2002).
   PubMed Web of Science ®Google Scholar
• Park JY, Takahara N, Gabriele A et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes49(7), 1239–1248 (2000).
   PubMed Web of Science ®Google Scholar
• Toth C, Rong LL, Yang C et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes57(4), 1002–1017 (2008).
   PubMed Web of Science ®Google Scholar
• Rask-MadsenC, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler. Thromb. Vasc. Biol.25(3), 487–496 (2005).
   PubMed Web of Science ®Google Scholar
• Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J. Biol. Chem.276(32), 30392–30398 (2001).
   PubMed Web of Science ®Google Scholar
• Kuboki K, Jiang ZY, Takahara N et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation101(6), 676–681 (2000).
   PubMed Web of Science ®Google Scholar
• Federici M, Pandolfi A, De Filippis EA et al. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation109(3), 399–405 (2004).
   PubMedGoogle Scholar
• Vicent D, Ilany J, Kondo T et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest.111(9), 1373–1380 (2003).
   PubMedGoogle Scholar
• Jiang ZY, Lin YW, Clemont A et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest.104(4), 447–457 (1999).
   PubMed Web of Science ®Google Scholar
• Cusi K, Maezono K, Osman A et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest.105(3), 311–320 (2000).
   PubMed Web of Science ®Google Scholar
• He Z, Opland DM, Way KJ et al. Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler. Thromb. Vasc. Biol.26(4), 787–793 (2006).
   PubMed Web of Science ®Google Scholar
• Naruse K, Rask-Madsen C, Takahara N et al. Activation of vascular protein kinase C-β inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes55(3), 691–698 (2006).
   PubMed Web of Science ®Google Scholar
• Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest.100(9), 2158–2169 (1997).
   PubMed Web of Science ®Google Scholar
• Geraldes P, Yagi K, Ohshiro Y et al. Selective regulation of heme oxygenase-1 expression and function by insulin through IRS1/phosphoinositide 3-kinase/Akt-2 pathway. J. Biol. Chem.283(49), 34327–34336 (2008).
   PubMed Web of Science ®Google Scholar
• Farhangkhoee H, Khan ZA, Mukherjee S et al. Heme oxygenase in diabetes-induced oxidative stress in the heart. J. Mol. Cell Cardiol.35(12), 1439–1448 (2003).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Haneda M, Koya D, Maeda S, Isshiki K, Kikkawa R. Enhancement of glomerular heme oxygenase-1 expression in diabetic rats. Diabetes Res. Clin. Pract.52(2), 85–96 (2001).
   PubMed Web of Science ®Google Scholar
• Cukiernik M, Mukherjee S, Downey D, Chakabarti S. Heme oxygenase in the retina in diabetes. Curr. Eye Res.27(5), 301–308 (2003).
   PubMed Web of Science ®Google Scholar
• Abraham NG, Kushida T, McClung J et al. Heme oxygenase-1 attenuates glucose-mediated cell growth arrest and apoptosis in human microvessel endothelial cells. Circ. Res.93(6), 507–514 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Giordano FJ, Gerber HP, Williams SP et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl Acad. Sci. USA98(10), 5780–5785 (2001).
   PubMed Web of Science ®Google Scholar
• Jiang ZY, He Z, King BL et al. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J. Biol. Chem.278(34), 31964–31971 (2003).
   PubMed Web of Science ®Google Scholar
• Poulaki V, Qin W, Joussen AM et al. Acute intensive insulin therapy exacerbates diabetic blood–retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF. J. Clin. Invest.109(6), 805–815 (2002).
   PubMed Web of Science ®Google Scholar
• Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J. Biol. Chem.275(28), 21695–21702 (2000).
   PubMed Web of Science ®Google Scholar
• Chou E, Suzuma I, Way KJ et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation105(3), 373–379 (2002).
   PubMed Web of Science ®Google Scholar
• Yoon YS, Uchida S, Masuo O et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation111(16), 2073–2085 (2005).
   PubMed Web of Science ®Google Scholar
• Pandolfi A, Solini A, Pellegrini G et al. Selective insulin resistance affecting nitric oxide release but not plasminogen activator inhibitor-1 synthesis in fibroblasts from insulin-resistant individuals. Arterioscler. Thromb. Vasc. Biol.25(11), 2392–2397 (2005).
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr. Rev.28(5), 463–491 (2007).
   PubMed Web of Science ®Google Scholar
• Morisco C, Marrone C, Trimarco V et al. Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression. Cardiovasc. Res.76(3), 453–464 (2007).
   PubMedGoogle Scholar
• Oliver FJ, de la Rubia G, Feener EP et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J. Biol. Chem.266(34), 23251–23256 (1991).
   PubMed Web of Science ®Google Scholar
• Arcaro G, Cretti A, Balzano S et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation105(5), 576–582 (2002).
   PubMed Web of Science ®Google Scholar
• Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest.97(11), 2601–2610 (1996).
   PubMed Web of Science ®Google Scholar
• Rask-Madsen C, Ihlemann N, Krarup T et al. Insulin therapy improves insulin-stimulated endothelial function in patients with Type 2 diabetes and ischemic heart disease. Diabetes50(11), 2611–2618 (2001).
   PubMed Web of Science ®Google Scholar
• Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab.3(1), 46–56 (2007).
   PubMedGoogle Scholar
• Standaert ML, Bandyopadhyay G, Kanoh Y, Sajan MP, Farese RV. Insulin and PIP3 activate PKC-zeta by mechanisms that are both dependent and independent of phosphorylation of activation loop (T410) and autophosphorylation (T560) sites. Biochemistry40(1), 249–255 (2001).
   PubMedGoogle Scholar
• Christiansen JS, Gammelgaard J, Frandsen M, Parving HH. Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics. Diabetologia20(4), 451–456 (1981).
   PubMed Web of Science ®Google Scholar
• Ditzel J, Schwartz M. Abnormally increased glomerular filtration rate in short-term insulin-treated diabetic subjects. Diabetes16(4), 264–267 (1967).
   PubMed Web of Science ®Google Scholar
• Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int.19(3), 410–415 (1981).
   PubMed Web of Science ®Google Scholar
• Viberti GC. Early functional and morphological changes in diabetic nephropathy. Clin. Nephrol.12(2), 47–53 (1979).
   PubMedGoogle Scholar
• O’Donnell MP, Kasiske BL, Keane WF. Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J.2(8), 2339–2347 (1988).
   PubMedGoogle Scholar
• Ruan X, Arendshorst WJ. Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats. Am. J. Physiol.270(6 Pt 2), F945–F952 (1996).
   Web of Science ®Google Scholar
• Craven PA, Caines MA, DeRubertis FR. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism36(1), 95–103 (1987).
   PubMed Web of Science ®Google Scholar
• Perico N, Benigni A, Gabanelli M et al. Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes41(4), 533–538 (1992).
   PubMedGoogle Scholar
• Feke GT, Buzney SM, Ogasawara H et al. Retinal circulatory abnormalities in Type 1 diabetes. Invest. Ophthalmol. Vis. Sci.35(7), 2968–2975 (1994).
   PubMed Web of Science ®Google Scholar
• Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest. Ophthalmol. Vis. Sci.37(5), 886–897 (1996).
   PubMed Web of Science ®Google Scholar
• Clermont AC, Brittis M, Shiba T, McGovern T, King GL, Bursell SE. Normalization of retinal blood flow in diabetic rats with primary intervention using insulin pumps. Invest. Ophthalmol. Vis. Sci.35(3), 981–990 (1994).
   PubMed Web of Science ®Google Scholar
• Kohner EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes44(6), 603–607 (1995).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med.331(22), 1480–1487 (1994).
   PubMed Web of Science ®Google Scholar
• Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes46(Suppl. 2), S31–S37 (1997).
   PubMed Web of Science ®Google Scholar
• Uehara K, Yamagishi S, Otsuki S, Chin S, Yagihashi S. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes53(12), 3239–3247 (2004).
   PubMedGoogle Scholar
• Nakamura J, Kato K, Hamada Y et al. A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes48(10), 2090–2095 (1999).
   PubMed Web of Science ®Google Scholar
• Haneda M, Kikkawa R, Horide N et al. Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells. Diabetologia34(3), 198–200 (1991).
   PubMedGoogle Scholar
• Fumo P, Kuncio GS, Ziyadeh FN. PKC and high glucose stimulate collagen α 1 (IV) transcriptional activity in a reporter mesangial cell line. Am. J. Physiol.267(4 Pt 2), F632–F638 (1994).
   PubMedGoogle Scholar
• Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc. Natl Acad. Sci. USA90(5), 1814–1818 (1993).
   PubMed Web of Science ®Google Scholar
• Shankland SJ, Scholey JW, Ly H, Thai K. Expression of transforming growth factor-β 1 during diabetic renal hypertrophy. Kidney Int.46(2), 430–442 (1994).
   PubMed Web of Science ®Google Scholar
• Edwards AS, Faux MC, Scott JD, Newton AC. Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C βII. J. Biol. Chem.274(10), 6461–6468 (1999).
   PubMedGoogle Scholar
• Chiu R, Boyle WJ, Meek J, Smeal T, Hunter T, Karin M. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell54(4), 541–552 (1988).
   PubMed Web of Science ®Google Scholar
• Ohshiro Y, Ma RC, Yasuda Y et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cβ-null mice. Diabetes55(11), 3112–3120 (2006).
   PubMed Web of Science ®Google Scholar
• Oliver JA. Adenylate cyclase and protein kinase C mediate opposite actions on endothelial junctions. J. Cell Physiol.145(3), 536–542 (1990).
   PubMed Web of Science ®Google Scholar
• Lynch JJ, Ferro TJ, Blumenstock FA, Brockenauer AM, Malik AB. Increased endothelial albumin permeability mediated by protein kinase C activation. J. Clin. Invest.85(6), 1991–1998 (1990).
   PubMed Web of Science ®Google Scholar
• Nagpala PG, Malik AB, Vuong PT, Lum H. Protein kinase C β 1 overexpression augments phorbol ester-induced increase in endothelial permeability. J. Cell Physiol.166(2), 249–255 (1996).
   PubMed Web of Science ®Google Scholar
• Wolf BA, Williamson JR, Easom RA, Chang K, Sherman WR, Turk J. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J. Clin. Invest.87(1), 31–38 (1991).
   PubMed Web of Science ®Google Scholar
• Xia P, Aiello LP, Ishii H et al. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest.98(9), 2018–2026 (1996).
   PubMed Web of Science ®Google Scholar
• Gamou S, Shimizu N. Calphostin-C stimulates epidermal growth factor receptor phosphorylation and internalization via light-dependent mechanism. J. Cell Physiol.158(1), 151–159 (1994).
   PubMedGoogle Scholar
• Katsura Y, Okano T, Noritake M et al. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care21(10), 1759–1763 (1998).
   PubMed Web of Science ®Google Scholar
• Pfeiffer A, Schatz H. Diabetic microvascular complications and growth factors. Exp. Clin. Endocrinol. Diabetes103(1), 7–14 (1995).
   PubMedGoogle Scholar
• Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest.100(1), 115–126 (1997).
   PubMed Web of Science ®Google Scholar
• Jirousek MR, Gillig JR, Gonzalez CM et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C β. J. Med. Chem.39(14), 2664–2671 (1996).
   PubMed Web of Science ®Google Scholar
• Bursell SE, King GL. Can protein kinase C inhibition and vitamin ε prevent the development of diabetic vascular complications? Diabetes Res. Clin. Pract.45(2–3), 169–182 (1999).
   PubMed Web of Science ®Google Scholar
• Orr JW, Keranen LM, Newton AC. Reversible exposure of the pseudosubstrate domain of protein kinase C by phosphatidylserine and diacylglycerol. J. Biol. Chem.267(22), 15263–15266 (1992).
   PubMed Web of Science ®Google Scholar
• McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J. Biol. Chem.274(3), 1715–1722 (1999).
   PubMed Web of Science ®Google Scholar
• Ron D, Luo J, Mochly-Rosen D. C2 region-derived peptides inhibit translocation and function of β protein kinase C in vivo. J. Biol. Chem.270(41), 24180–24187 (1995).
   PubMed Web of Science ®Google Scholar
• Dorn GW 2nd, Souroujon MC, Liron T et al. Sustained in vivo cardiac protection by a rationally designed peptide that causes ε protein kinase C translocation. Proc. Natl Acad. Sci. USA96(22), 12798–12803 (1999).
   PubMed Web of Science ®Google Scholar
• Parmer TG, Ward MD, Hait WN. Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Differ.8(3), 327–334 (1997).
   PubMedGoogle Scholar
• Kunisaki M, Bursell SE, Clermont AC et al. Vitamin ε prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am. J. Physiol.269(2 Pt 1), E239–E246 (1995).
   PubMedGoogle Scholar
• Bursell SE, Takagi C, Clermont AC et al. Specific retinal diacylglycerol and protein kinase C β isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest. Ophthalmol. Vis. Sci.38(13), 2711–2720 (1997).
   PubMed Web of Science ®Google Scholar
• Bursell SE, Clermont AC, Aiello LP et al. High-dose vitamin ε supplementation normalizes retinal blood flow and creatinine clearance in patients with Type 1 diabetes. Diabetes Care22(8), 1245–1251 (1999).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin ε supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3), 154–160 (2000).
   PubMed Web of Science ®Google Scholar
• Economides PA, Khaodhiar L, Caselli A et al. The effect of vitamin ε on endothelial function of micro- and macrocirculation and left ventricular function in Type 1 and Type 2 diabetic patients. Diabetes54(1), 204–211 (2005).
   PubMed Web of Science ®Google Scholar
• Bowling N, Walsh RA, Song G et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation,99(3), 384–391 (1999).
   PubMed Web of Science ®Google Scholar
• McGill JB, King GL, Berg PH et al. Clinical safety of the selective PKC-β inhibitor, ruboxistaurin. Expert Opin. Drug Saf.5(6), 835–845 (2006).
   PubMed Web of Science ®Google Scholar
• Nonaka A, Kiryu J, Tsujikawa A et al. PKC-β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest. Ophthalmol. Vis. Sci.41(9), 2702–2706 (2000).
   PubMed Web of Science ®Google Scholar
• Arikawa E, Ma RC, Isshiki K et al. Effects of insulin replacements, inhibitors of angiotensin, and PKCβ’s actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes56(5), 1410–1420 (2007).
   PubMedGoogle Scholar
• Campochiaro PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci.45(3), 922–931 (2004).
   PubMed Web of Science ®Google Scholar
• Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest.102(4), 783–791 (1998).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci.47(1), 86–92 (2006).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Davis MD, Girach A et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113(12), 2221–2230 (2006).
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation108(17), 2154–2169 (2003).
   PubMed Web of Science ®Google Scholar
• Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int.55(1), 1–28 (1999).
   PubMed Web of Science ®Google Scholar
• Parving HH, Hommel E, Mathiesen E et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br. Med. J. (Clin. Res. Ed.)296(6616), 156–160 (1988).
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in Type 2 diabetes. Diabetes Care28(11), 2686–2690 (2005).
   PubMed Web of Science ®Google Scholar
• Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest.90(6), 2548–2554 (1992).
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br. J. Pharmacol.130(5), 963–974 (2000).
   PubMed Web of Science ®Google Scholar
• McVeigh GE, Brennan GM, Johnston GD et al. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia35(8), 771–776 (1992).
   PubMed Web of Science ®Google Scholar
• Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase Cβ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ. Res.90(1), 107–111 (2002).
   PubMed Web of Science ®Google Scholar
• Hink U, Li H, Mollnau H et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res.88(2), E14–E22 (2001).
   PubMed Web of Science ®Google Scholar
• Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium11(2), 89–97 (2004).
   PubMed Web of Science ®Google Scholar
• Cosentino F, Eto M, De Paolis P et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation107(7), 1017–1023 (2003).
   PubMed Web of Science ®Google Scholar
• Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with Type II diabetes mellitus. Circulation106(14), 1783–1787 (2002).
   PubMed Web of Science ®Google Scholar
• Mehta NN, Sheetz M, Price K et al. Selective PKC β inhibition with ruboxistaurin and endothelial function in Type-2 diabetes mellitus. Cardiovasc. Drugs Ther.23(1), 17–24 (2009).
   PubMedGoogle Scholar
• Harja E, Chang JS, Lu Y et al. Mice deficient in PKCβ and apolipoprotein ε display decreased atherosclerosis. FASEB J.23(4), 1081–1091 (2009).
   PubMedGoogle Scholar
• Balafanova Z, Bolli R, Zhang J et al. Nitric oxide (NO) induces nitration of protein kinase Cε (PKCε), facilitating PKCε translocation via enhanced PKCε -RACK2 interactions: a novel mechanism of no-triggered activation of PKCε. J. Biol. Chem.277(17), 15021–15027 (2002).
   PubMed Web of Science ®Google Scholar
• Nagareddy PR, Soliman H, Lin G et al. Selective inhibition of protein kinase C β(2) attenuates inducible nitric oxide synthase-mediated cardiovascular abnormalities in streptozotocin-induced diabetic rats. Diabetes58(10), 2355–2364 (2009).
   PubMedGoogle Scholar